[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100373794":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":45,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Sichuan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"cell_therapy","EXPERIMENTAL","tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times",[13],"Biological: DC vaccine subcutaneous administration",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","DC vaccine subcutaneous administration","subcutaneous administration",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Qiu Li","CONTACT","+86 028-85422589","liqiu@scu.edu.cn",[28],{"facility":23,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Chengdu","Sichuan","610041","China","CN",{"type":36,"coordinates":37},"Point",[38,39],104.06667,30.66667,{"lat":39,"lon":38},[42,44],{"name":43,"role":24,"phone":25,"phoneExt":20,"email":26},"Qiu Li, PhD",{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Zhen-Yu Ding","Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University","100373794","phase-1-personalized-dc-vaccine-for-postoperative-cancer-100373794",false,"NCT04147078","Personalized DC Vaccine for Postoperative Cancer","Adjuvant Treatment in Cancer Patients with Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial","Inclusion Criteria:\n\n* Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation\n* Anticipated life time \\> 3month\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n* Adequate organ functions\n\nExclusion Criteria:\n\n* Any evidence of tumor metastasis or co-existing malignant disease\n* Tumor emergency\n* Abnormal coagulation condition\n* Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection\n* Concomitant tumors\n* Immunological co-morbidities","ALL","18 Years","100 Years",{"count":60,"type":61},80,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.",[67,68,69,70],"Gastric Cancer","Hepatocellular Carcinoma","Non-Small-Cell Lung Cancer","Colon Rectal Cancer",[72,73,74,75,76],"Cell therapy","safety","clinical efficacy","adjuvant treatment","locally advanced cancer","2025-02-25",{"date":79,"type":80},"2025-02-28","ACTUAL",{"date":82,"type":80},"2019-06-01",{"date":84,"type":61},"2026-06-01",{"name":5,"class":6},1]